Want to see GB:COG full AI Analyst Report?
COG Stock Chart & Stats
28.00 p
-0.58 p(-1.49%)
At close: 4:00 PM EST
28.00 p
-0.58 p(-1.49%)
Day’s Range― - ―
52-Week Range23.90 p - 45.00 p
Previous CloseN/A
Volume352.00
Average Volume (3M)32.00K
Market Cap
£15.60M
Enterprise Value16.03M
Total Cash (Recent Filing)£1.13M
Total Debt (Recent Filing)£858.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,629,700
10 Day Avg. Volume24,264
30 Day Avg. Volume32,004
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)4.06
Price to Sales (P/S)1.29
P/FCF Ratio-46.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£72.00Price Target Upside157.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£11.61M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsHigh gross margins (≈74%–81%) indicate durable unit economics for the software/tests business. This margin cushion supports investment in R&D and service delivery, helping the business absorb SG&A and trial-specific costs and improving the path to profitability if revenues stabilize.
Improved Balance Sheet And Lower LeverageMaterial reduction in debt and stronger equity increases financial resilience, lowering refinancing and covenant risk. A healthier balance sheet provides runway to support ongoing trials, invest selectively, and negotiate with partners without immediate liquidity pressure.
Niche Recurring Revenue Model In Clinical ResearchThe business model sells licensed cognitive tests and services into clinical trials, driving recurring, contract-linked revenue and long-term client relationships with pharma/CROs. This specialization creates tailored offerings and potential high switching costs, supporting revenue durability when study flow is steady.
Bears Say
Multi-year Operating And Net LossesSustained operating and net losses over multiple years show structural profitability challenges. Persistent losses constrain reinvestment, increase reliance on external funding, and mean shareholder returns remain negative until operating leverage or revenue growth meaningfully reverses the trend.
Negative Cash Flow And Weak Cash GenerationContinued negative operating and free cash flow indicates the business is not yet self-sustaining. Even with improved burn in 2025, reliance on financing or equity raises remains a structural vulnerability that can limit strategic flexibility and slow product or sales investments.
Revenue Decline And VolatilityDeclining and volatile revenue reduces leverage over fixed costs and makes scaling margins difficult. Lower study volumes or contract sizes can persist across quarters, pressuring profitability and cash flow unless the company secures new long-term contracts or expands into adjacent markets.
Cambridge Cognition Holdings News
COG FAQ
What was Cambridge Cognition Holdings Plc’s price range in the past 12 months?
Cambridge Cognition Holdings Plc lowest share price was 23.90 p and its highest was 45.00 p in the past 12 months.
What is Cambridge Cognition Holdings Plc’s market cap?
Cambridge Cognition Holdings Plc’s market cap is £15.60M.
When is Cambridge Cognition Holdings Plc’s upcoming earnings report date?
Cambridge Cognition Holdings Plc’s upcoming earnings report date is Sep 29, 2026 which is in 85 days.
How were Cambridge Cognition Holdings Plc’s earnings last quarter?
Cambridge Cognition Holdings Plc released its earnings results on Apr 13, 2026. The company reported -0.015 p earnings per share for the quarter, missing the consensus estimate of -0.006 p by -0.009 p.
Is Cambridge Cognition Holdings Plc overvalued?
According to Wall Street analysts Cambridge Cognition Holdings Plc’s price is currently Undervalued.
Does Cambridge Cognition Holdings Plc pay dividends?
Cambridge Cognition Holdings Plc does not currently pay dividends.
What is Cambridge Cognition Holdings Plc’s EPS estimate?
Cambridge Cognition Holdings Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cambridge Cognition Holdings Plc have?
Cambridge Cognition Holdings Plc has 46,629,700 shares outstanding.
What happened to Cambridge Cognition Holdings Plc’s price movement after its last earnings report?
Cambridge Cognition Holdings Plc reported an EPS of -0.015 p in its last earnings report, missing expectations of -0.006 p. Following the earnings report the stock price went down -1.282%.
Which hedge fund is a major shareholder of Cambridge Cognition Holdings Plc?
Currently, no hedge funds are holding shares in GB:COG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
COG Stock 12 Month Forecast
Average Price Target
72.00 p
▲(157.14% Upside)
Technical Analysis
Options Prices
Currently, No data available
---